Immunotherapy revolutionizes frontline treatment in advanced RCC

Michael E. Hurwitz, MD, PhD, an associate professor of Internal Medicine at the Yale Cancer Center, discusses how immune checkpoint inhibitor–based combination have dramatically altered the frontline treatment paradigm for patients with advanced renal cell carcinoma.

Related Videos
Dr. Michael Stifelman in an interview with Urology Times
Teona Iarajuli in an interview with Urology Times
Expert on prostate cancer
Veda Giri, MD, answers a question during a Zoom video interview
Madison Novosel, BA, in an interview with Urology Times
Genetic testing for prostate cancer | Image credit: © ktsdesign - stock.adobe.com
Veda Giri, MD, answers a question during a Zoom video interview
DNA molecules
Dr. Daniel P. Petrylak in an interview with Urology Times
© 2023 MJH Life Sciences

All rights reserved.